Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 9/20 | 0.51 |
| ▸ | LIPG | Q9Y5X9 | 9/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | F11 | P03951 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257763 | 0.86 | DGAT1 (0.55) | LPLLIPGLTA4HDGAT1CA1 | |
| SCHEMBL3517704 | 0.84 | LIPG (0.67) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL427591 | 0.82 | CA1 (0.56) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL12260770 | 0.79 | LIPG (0.56) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL25405585 | 0.79 | LPL (0.53) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL428836 | 0.79 | LPL (0.53) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL428838 | 0.79 | LPL (0.53) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL430495 | 0.79 | LPL (0.53) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL12260766 | 0.78 | LIPG (0.58) | LPLLIPGDGAT1CA1CA2 | |
| SCHEMBL2557178 | 0.77 | CA1 (0.51) | LPLLIPGDGAT1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9180123-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150182513-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2015-07-02 | — | — | US | disclosed |
| US-9018384-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2015-04-28 | — | — | US | disclosed |
| US-20140343031-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. (US) | 2014-11-20 | — | — | US | disclosed |
| EP-2512474-B1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8846933-B2 | N-link hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140128363-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER (US) | 2014-05-08 | — | — | US | disclosed |
| US-8664401-B2 | N-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-03-04 | — | — | US | disclosed |
| EP-2512474-A1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120258948-A1 | N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | PFIZER INC. | 2012-10-11 | — | — | US | disclosed |
| WO-2011073845-A1 | N-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182513-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | LPL 1201/4885LIPG 1011/4885LTA4H 181/4885 |
| US-20120258948-A1 | N-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, LCT, HAX1 | LPL 541/4885LIPG 482/4885LTA4H 78/4885 |
| US-20140128363-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | LPL 1201/4885LIPG 1011/4885LTA4H 181/4885 |
| US-20140343031-A1 | N-Link Hydroxamic Acid Derivatives Useful As Antibacterial Agents | LPXN, NAAA, AGXT | LPL 1201/4885LIPG 1011/4885LTA4H 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.